About verrica pharmaceuticals inc - VRCA
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
VRCA At a Glance
Verrica Pharmaceuticals, Inc.
44 West Gay Street
West Chester, Pennsylvania 19380
| Phone | 1-434-453-3300 | Revenue | 35.58M | |
| Industry | Pharmaceuticals: Major | Net Income | -17,886,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 370.222% | |
| Fiscal Year-end | 12 / 2026 | Employees | 76 | |
| View SEC Filings |
VRCA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.488 |
| Price to Book Ratio | 5.77 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.378 |
| Enterprise Value to Sales | 1.687 |
| Total Debt to Enterprise Value | 0.027 |
VRCA Efficiency
| Revenue/Employee | 468,118.421 |
| Income Per Employee | -235,342.105 |
| Receivables Turnover | 6.592 |
| Total Asset Turnover | 0.697 |
VRCA Liquidity
| Current Ratio | 2.469 |
| Quick Ratio | 2.333 |
| Cash Ratio | 1.834 |
VRCA Profitability
| Gross Margin | 90.328 |
| Operating Margin | -33.558 |
| Pretax Margin | -50.274 |
| Net Margin | -50.274 |
| Return on Assets | -35.024 |
| Return on Equity | -240.355 |
| Return on Total Capital | -67.817 |
| Return on Invested Capital | -74.367 |
VRCA Capital Structure
| Total Debt to Total Equity | 6.592 |
| Total Debt to Total Capital | 6.184 |
| Total Debt to Total Assets | 3.432 |
| Long-Term Debt to Equity | 3.577 |
| Long-Term Debt to Total Capital | 3.356 |